FMS Quote, Financials, Valuation and Earnings

Bayer AG has a net margin of 1.32% compared to Fresenius Medical Care AG's net margin of -2.86%. Fresenius Medical Care AG's return on equity of 3.56% beat Bayer AG's return on equity of -7.79%.

Fresenius Medical Care AG has a consensus price target of $27.56, signalling upside risk potential of 16.58%. On the other hand Bayer AG has an analysts' consensus of $8.32 which suggests that it could grow by 33.12%. Given that Bayer AG has higher upside potential than Fresenius Medical Care AG, analysts believe Bayer AG is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.935, which suggesting that the stock is 6.546% less volatile than S&P 500. In comparison Bayer AG has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.097%.

Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.72%. Bayer AG offers a yield of 0.47% to investors and pays a quarterly dividend of $0.03 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. Bayer AG pays out -5.13% of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.4B, which are smaller than Bayer AG quarterly revenues of $12.5B. Fresenius Medical Care AG's net income of $71.3M is higher than Bayer AG's net income of -$357.1M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 23.67x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.66x versus 0.49x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.

BioNTech SE has a net margin of 1.32% compared to Fresenius Medical Care AG's net margin of 21.81%. Fresenius Medical Care AG's return on equity of 3.56% beat BioNTech SE's return on equity of -3.39%.

Fresenius Medical Care AG has a consensus price target of $27.56, signalling upside risk potential of 16.58%. On the other hand BioNTech SE has an analysts' consensus of $142.37 which suggests that it could grow by 23.98%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.935, which suggesting that the stock is 6.546% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.943%.

Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.72%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.4B, which are larger than BioNTech SE quarterly revenues of $1.3B. Fresenius Medical Care AG's net income of $71.3M is lower than BioNTech SE's net income of $276.6M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 23.67x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.66x versus 9.27x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 1.32% compared to Fresenius Medical Care AG's net margin of 68.44%. Fresenius Medical Care AG's return on equity of 3.56% beat CureVac NV's return on equity of 21.3%.

Fresenius Medical Care AG has a consensus price target of $27.56, signalling upside risk potential of 16.58%. On the other hand CureVac NV has an analysts' consensus of $6.50 which suggests that it could grow by 104.69%. Given that CureVac NV has higher upside potential than Fresenius Medical Care AG, analysts believe CureVac NV is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.935, which suggesting that the stock is 6.546% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.72%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.4B, which are larger than CureVac NV quarterly revenues of $543.2M. Fresenius Medical Care AG's net income of $71.3M is lower than CureVac NV's net income of $371.8M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 23.67x while CureVac NV's PE ratio is 3.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.66x versus 1.21x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Merck KGaA has a net margin of 1.32% compared to Fresenius Medical Care AG's net margin of 12.31%. Fresenius Medical Care AG's return on equity of 3.56% beat Merck KGaA's return on equity of 9.8%.

Fresenius Medical Care AG has a consensus price target of $27.56, signalling upside risk potential of 16.58%. On the other hand Merck KGaA has an analysts' consensus of $37.10 which suggests that it could grow by 35.45%. Given that Merck KGaA has higher upside potential than Fresenius Medical Care AG, analysts believe Merck KGaA is more attractive than Fresenius Medical Care AG.

Fresenius Medical Care AG has a beta of 0.935, which suggesting that the stock is 6.546% less volatile than S&P 500. In comparison Merck KGaA has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.82599999999999%.

Fresenius Medical Care AG has a quarterly dividend of $0.64 per share corresponding to a yield of 2.72%. Merck KGaA offers a yield of 1.72% to investors and pays a quarterly dividend of $0.47 per share. Fresenius Medical Care AG pays 64.91% of its earnings as a dividend. Merck KGaA pays out 10.23% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Fresenius Medical Care AG quarterly revenues are $5.4B, which are smaller than Merck KGaA quarterly revenues of $5.8B. Fresenius Medical Care AG's net income of $71.3M is lower than Merck KGaA's net income of $711M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 23.67x while Merck KGaA's PE ratio is 19.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.66x versus 2.60x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.